TICKERNERD
Menu
GERNGERNHealthcare · Biotechnology

GERN Stock Forecast: Geron Corp. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$1.35
−1.46% on the day

The 5 Wall Street analysts covering Geron Corp. hold a median 12-month price target of $4 — +196.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 52 of 100 as at 12 Sept 2026 — in the upper half.

Market cap
$867.3M
Ticker Nerd rank
52 / 100
Median analyst target
$4.00
Analysts covering
5
Revenue$57.5M+17.2% y/y
Operating income−$12.7M
Net income−$16.7M
Free cash flow−$16.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−10.6%
1M
−17.2%
YTD
+2.3%
1Y
+2.3%
From 52W high
−30.8%
From 52W low
+26.2%
$1.07
$1.95
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

GERN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Geron Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
52 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
89
Quality
83
Volatility
59
Growth
48
Size
46
Revisions
46
Momentum
44
Issuance
41
Accruals
25

Value (89): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Accruals (25): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

GERN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on GERN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00$5.00$6.00Oct 25Jan 26Apr 26Jul 26GERNHigh $6.00Median $4.00Low $3.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
4 Buy1 Hold0 Sell
Low $3.00Median $4.00High $6.00

The green dot is the last close — the median target sits +196.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
5 Nov 2025NeedhamMaintainsBuy$5.00 → $4.00
5 Nov 2025NeedhamMaintainsBuy—
10 July 2025Goldman SachsReinstatesSell$1.00
8 May 2025ScotiabankDowngradeSector Perform—
12 Mar 2025HC Wainwright & Co.ReiteratesNeutral—
12 Mar 2025NeedhamReiteratesBuy—
27 Feb 2025BarclaysMaintainsOverweight—
27 Feb 2025NeedhamMaintainsBuy—
27 Feb 2025ScotiabankMaintainsSector Outperform—
27 Feb 2025StifelMaintainsBuy—
26 Feb 2025HC Wainwright & Co.DowngradeNeutral—
18 Feb 2025B. Riley SecuritiesMaintainsBuy—
13 Jan 2025NeedhamMaintainsBuy—
13 Dec 2024NeedhamReiteratesBuy—
10 Dec 2024HC Wainwright & Co.ReiteratesBuy—
6 Nov 2024HC Wainwright & Co.ReiteratesBuy—
5 Nov 2024HC Wainwright & Co.InitiatesBuy—
16 Oct 2024ScotiabankInitiatesSector Outperform—
9 Sept 2024Leerink PartnersInitiatesOutperform—
9 Aug 2024NeedhamReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. GERN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

GERN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Geron Corp. returned +2.3% against +17.5% for the S&P 500, dividends included.

GERN vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140Oct 25Jan 26Apr 26Jul 26GERNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

GERN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Geron Corp. (GERN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−10.3×

Cheaper than 93% of US stocks

Price / sales
4.2×

Cheaper than 29% of US stocks

Price / book
4.0×

Cheaper than 26% of US stocks

EV / EBITDA
−19.8×

Cheaper than 89% of US stocks

Growth & margins
Revenue growth (YoY)
17.2%

Higher than 66% of US stocks

Earnings growth (YoY)
17.2%

Higher than 55% of US stocks

Gross margin
83.9%

Higher than 93% of US stocks

Operating margin
−22.0%

Higher than 21% of US stocks

Net margin
−33.1%

Higher than 13% of US stocks

Returns & dividend
Return on equity
−28.3%

Higher than 28% of US stocks

Return on assets
−4.1%

Higher than 33% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Geron Corp. (GERN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Geron Corp. has a market value of $867.3M and an enterprise value of $688.6M.

  • Revenue in the twelve months to 30 June 2026: $204.6M. The latest quarter grew 17.2% year on year.

  • Net income over the same four quarters: −$67.6M, a −33.1% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.11.

  • Free cash flow in the twelve months to 30 June 2026: −$114.8M.

  • Shares outstanding: 642.5M.

  • Trailing P/E: −10.3×; forward P/E: 33.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Geron Corp. employs 258 people — $793K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

GERN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
GERNGeron Corp.$867.3M
52
IMMXImmix Biopharma, Inc.$864.2M
34
ARDXArdelyx, Inc.$869.8M
50
TBPHTheravance Biopharma, Inc.$856.6M
89
RIGLRigel Pharmaceuticals, Inc.$874.0M
77
AVTXAvalo Therapeutics, Inc.$847.4M
38
WVEWave Life Sciences, Inc.$883.0M
14

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Geron Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest GERN news & analysis

Geron Sees RYTELO Revenue Near High End of 2026 Guidance as Community Use Expands

MarketBeat · 13 Sept 2026positive

Geron stated that full-year net revenue from RYTELO is expected to land in the mid-to-high end of its previously stated range, approximately $230 million to $240 million, as the company continues to expand use of the telomerase inhibitor in lower-risk myelodysplastic syndromes.

Why it matters — The company's expectation that RYTELO revenue will reach the upper portion of its guidance range signals continued commercial growth and broader adoption in the community setting, which GERN watchers would view favorably.

Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?

PRNewsWire · 2 Sept 2026negative

A law firm is encouraging Geron Corporation shareholders to contact them regarding potential breaches of fiduciary duties by company insiders. The firm offers to handle matters on a contingent fee basis at no cost to shareholders.

Why it matters — GERN watchers would care because the notice raises a potential legal and governance concern for the company regarding insider conduct toward shareholders.

Geron to Present at Upcoming Investor Conferences

GlobeNewsWire · 2 Sept 2026neutral

Geron Corporation announced that members of its management team are scheduled to participate in several upcoming investor conferences. The hematology-focused biopharmaceutical company made this disclosure via a press release from Foster City, California.

Why it matters — The scheduled conference appearances provide GERN watchers with opportunities for management to discuss the company's progress with investors and industry audiences.

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 18 Aug 2026neutral

Geron Corporation reported that, effective August 17, 2026, it granted stock options covering an aggregate of 311,250 shares of common stock to six newly hired employees as inducement grants material to their acceptance of employment. The grants were made under Nasdaq Listing Rule 5635(c)(4).

Why it matters — This disclosure reflects Geron's expansion through new hires and is a routine corporate governance filing that GERN watchers would note as part of the company's staffing growth.

Geron Corp: Management's Plan Taking Shape As Competition Heats Up In Myelofibrosis

Seeking Alpha · 18 Aug 2026neutral

Geron reported Q2'26 net product revenues of $57.5M from U.S. sales of Rytelo, up 11% from Q1'26. Management kept its 2026 revenue guidance unchanged but suggested revenues would likely reach the mid- to high-end of that range, while a potential competitor in myelofibrosis (KPTI) is pursuing approval in frontline disease and Geron is running a phase 3 study in relapsed/refractory myelofibrosis.

Why it matters — GERN watchers would care because the report covers Rytelo's revenue trajectory and management's guidance outlook, while also flagging competitive pressure in the myelofibrosis market as Geron advances its own phase 3 study.

FAQ

Frequently asked questions about GERN stock

What is the GERN stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Geron Corp. have a median 12-month price target of $4, with estimates ranging from $3 to $6. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is GERN stock a buy right now?

Of the 5 analysts covering Geron Corp., 4 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Geron Corp. 52 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank GERN?

As at 12 Sept 2026, Geron Corp. ranks 52 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (89 of 100).

Will GERN stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +196.3% from the last close, and Ticker Nerd's factor model ranks Geron Corp. 52 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the GERN stock forecast for 2030?

No analyst covering Geron Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GERN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $6 over the next 12 months.

How has GERN stock performed over the past year?

Geron Corp. returned +2.3% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Geron Corp. do?

Geron Corporation is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for blood cancers and related hematologic disorders. Its lead product is RYTELO (imetelstat), a telomerase inhibitor used in the treatment of adult patients with lower-risk myelodysplastic syndromes who have transfusion-dependent anemia.

What is the latest news on GERN?

The most recent item we track (MarketBeat, 13 Sept 2026): "Geron Sees RYTELO Revenue Near High End of 2026 Guidance as Community Use Expands". Geron stated that full-year net revenue from RYTELO is expected to land in the mid-to-high end of its previously stated range, approximately $230 million to $240 million, as the company continues to expand use of the telomerase inhibitor in lower-risk myelodysplastic syndromes.

Company

About Geron Corp.

Geron Corporation is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for blood cancers and related hematologic disorders. Its lead product is RYTELO (imetelstat), a telomerase inhibitor used in the treatment of adult patients with lower-risk myelodysplastic syndromes who have transfusion-dependent anemia. The company’s work centers on oncology programs that target abnormal blood-forming cells, with an emphasis on myeloid malignancies and other disorders of the bone marrow and blood. Geron Corporation serves the specialized hematology-oncology market by advancing targeted treatment options for patients with limited alternatives, supporting use across clinical practice, specialty care settings, and disease-focused treatment centers. Headquartered in Foster City, California, Geron Corporation is positioned as a focused biotechnology company built around telomerase inhibition and commercial therapy development.

CEO Mr. Harout Semerjian · 258 employees · United States · https://www.geron.com